Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is a record number of clinical trial presentations for an AACR Annual Meeting. The trials presented...
In the past couple of decades, progress against cancer has created a new generation of survivors. Today, more than 16.9 million people in the United States are cancer survivors. While their experiences are incredibly...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of NSCLCs harbor epidermal growth factor receptor (EGFR)-activating mutations. Treatment for EGFR-mutant NSCLC improved dramatically with the introduction of EGFR tyrosine kinase inhibitors (TKIs).
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers with high unmet medical need. The program aims to encourage innovation and translation of ideas...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or high response rates, they are not risk-free. Reports of immune-related adverse events (therapy-dependent toxicities caused...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence, asked the audience as he opened the “PD-1 Pandemonium: FDA Speaks with Industry on the Past, Present, and Future of PD-1 Drugs” regulatory science and policy session at the American Association for Cancer Research (AACR) Annual Meeting 2019 on Monday, April 1.
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including melanoma, lung cancer, head and neck cancer, bladder cancer, cervical cancer, liver cancer, stomach cancer, breast cancer, lymphoma, and to treat patients with any type of solid tumor that is microsatellite instability–high or mismatch repair–deficient.
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more than 15 percent of new cancer cases were attributed to carcinogenic infection, and the top...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and attack cancer cells. While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types.
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric antigen receptor (CAR) T-cell therapies for patients with advanced solid tumors.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More